Randomized trial from China suggests better functional independence ...

Time is of the essence in establishing the diagnosis of stroke and determining whether the patient is a candidate for thrombolytic therapy, ideally initiated within the “golden hour” after arrival at ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

In patients with acute ischemic stroke and elevated high-sensitivity cardiac troponin (hs-cTn), dynamic changes in hs-cTn are not helpful in identifying myocardial infarction (MI) or distinguishing MI ...

Please provide your email address to receive an email when new articles are posted on . Researchers engaged in a secondary analysis of the ESCAPE clinical trial in patients with acute ischemic stroke.

Former FDA Cardiovascular Division Director Norman Stockbridge, M.D., Ph.D. joins SABBradley Newman named Global Head of Manufacturing and Supply ChainChia-Wen Lee, Ph.D. appointed Global Head of ...

With one positive and one neutral trial, the jury is still out on whether intra-arterial hypothermia boosts functional outcomes.

Please provide your email address to receive an email when new articles are posted on . Researchers conducted a literature review for informed consent with acute ischemic stroke. Decisions should ...

A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...

Considering some unique trial features, the results should be seen “more as hypothesis-generating than practice-changing.” ...

Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced today that its investigational therapy, ...